CS
XBI icon

Capital Square’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Capital Square’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,191
Closed -$220K – 232
2025
Q3 		$220K Buy
+2,191
New +$197K 0.11% 174
2025
Q1 		– Sell
-2,700
Closed -$250K – 200
2024
Q4 		$250K Buy
2,700
+546
+25% +$52.9K 0.14% 147
2024
Q3 		$213K Sell
2,154
-44
-2% -$4.32K 0.13% 146
2024
Q2 		$217K Sell
2,198
-630
-22% -$56.5K 0.14% 132
2024
Q1 		$268K Buy
+2,828
New +$262K 0.19% 116

Other funds holding XBI

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Capital Square's XBI Position: Q4 2025 in Review

Capital Square sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2025, closing a stake of 2,191 shares — an estimated $220K sold.

Capital Square first reported a position in XBI in Q1 2024 and held it in 5 quarters. The position peaked at $268K in Q1 2024. 814 funds tracked by Wall St. Rank hold XBI as of Q4 2025.

  • Capital Square reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2025 after selling out during the quarter.
  • Capital Square sold 2,191 State Street SPDR S&P Biotech ETF shares in Q4 2025, an estimated $220K.
  • Capital Square first reported a position in State Street SPDR S&P Biotech ETF in Q1 2024 and held it in 5 quarters.
  • Capital Square's State Street SPDR S&P Biotech ETF position peaked at $268K in Q1 2024.
  • 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2025.

Based on Capital Square's 13F filing for Q4 2025, filed 13 Feb 2026.